Akshay Basi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Akshay Basi has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Jared K. Burks
Department of Leukemia, Division of Center Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
57 shared publications - Javier A. Gomez
Department of Leukemia, The University of Texas MD Anderson Cancer Center
53 shared publications - Christopher Alvarez-Breckenridge
Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
33 shared publications - Eleonora Dondossola
David H. Koch Center for Applied Research of Genitourinary Cancers and Genitourinary Medical Oncology Department, The University of Texas MD Anderson Cancer Center, Houston, Texas
33 shared publications - Emanuela Gentile
Department of Genitourinary Medical Oncology, David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas. 1
33 shared publications - Jianfeng Chen
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
33 shared publications
Latest Publications
- Open Access
Macrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint Blockade
Immune checkpoint inhibitors (ICIs) elicit durable responses in only a subset of patients with solid tumors, underscoring the need to define the cellular architectures that govern effective antitumor immunity. Here we identify a spatially organized multicellular immune unit comprising macrophages, cDC1s, CD4+ T-cells, and CD8+ T-cells that emerges in response to anti-CTLA-4 or dual checkpoint blockade. We term these structures tetrads. Using multiplexed imaging and spatial transcriptomics in mouse and human tumors, we show that tetrads assemble early during immune priming, depend on the ICOS-ICOSL pathway, and are enriched for ICOS+ Th1-like CD4+ T cells and ICOSL-high cDC1s. CD8+ T-cells within tetrads exhibit an activated, non-terminally differentiated state, while tetrad-associated macrophages display an interferon gamma-responsive program that sustains CD8+ T-cell function and prevents dysfunction. Functionally, ICOSL+ cDC1s are required for tumor eradication in vivo. In patients with bladder cancer treated with neoadjuvant dual checkpoint blockade, tetrad, but not triad or dyad formation correlates with clinical response. These findings establish tetrads as a fundamental cellular unit coordinating antitumor immunity and responsiveness to ICIs.
Open AccessMacrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint Blockade
Immune checkpoint inhibitors (ICIs) elicit durable responses in only a subset of patients with solid tumors, underscoring the need to define the cellular architectures that govern effective antitumor immunity. Here we identify a spatially organized multicellular immune unit comprising macrophages, cDC1s, CD4+ T-cells, and CD8+ T-cells that emerges in response to anti-CTLA-4 or dual checkpoint blockade. We term these structures tetrads. Using multiplexed imaging and spatial transcriptomics in mouse and human tumors, we show that tetrads assemble early during immune priming, depend on the ICOS-ICOSL pathway, and are enriched for ICOS+ Th1-like CD4+ T cells and ICOSL-high cDC1s. CD8+ T-cells within tetrads exhibit an activated, non-terminally differentiated state, while tetrad-associated macrophages display an interferon gamma-responsive program that sustains CD8+ T-cell function and prevents dysfunction. Functionally, ICOSL+ cDC1s are required for tumor eradication in vivo. In patients with bladder cancer treated with neoadjuvant dual checkpoint blockade, tetrad, but not triad or dyad formation correlates with clinical response. These findings establish tetrads as a fundamental cellular unit coordinating antitumor immunity and responsiveness to ICIs.
- 7 October 2025
- Published by MyJove Corporation
- No. 224,p. e68617
JoVE Video Dataset
When using traditional probe-based in situ hybridization (ISH) imaging detection methods, microRNAs (miRNAs) are difficult to capture due to their size, which ranges from 19 to 25 nucleotides. However, as miRNAs are key epigenetic regulators that contribute to normal physiology and numerous pathological conditions, understanding the spatiotemporal behavior of miRNAs is important to unravel their function at the cellular and subcellular levels. This creates a clear need for adequate detection and visualization techniques. Therefore, we created MicroRNA Amplification and Recognition through Locked-nucleic-acid in situ hybridizatioN (MARLIN), which was developed and optimized utilizing multiplex immunofluorescence staining, and locked nucleic acid (LNA) probes targeted to a miRNA. This method can quantify miRNA with multiplexed protein expression, which allows the quantification of intracellular and extracellular miRNA within the tumor microenvironment (TME) with high sensitivity and reproducibility. The combined use of miRNA detection and protein capture assays can also provide a comprehensive understanding of cellular functions and regulatory mechanisms within that TME.
- 7 October 2025
- Published by MyJove Corporation
- No. 224,p. e68617
JoVE Video Dataset
When using traditional probe-based in situ hybridization (ISH) imaging detection methods, microRNAs (miRNAs) are difficult to capture due to their size, which ranges from 19 to 25 nucleotides. However, as miRNAs are key epigenetic regulators that contribute to normal physiology and numerous pathological conditions, understanding the spatiotemporal behavior of miRNAs is important to unravel their function at the cellular and subcellular levels. This creates a clear need for adequate detection and visualization techniques. Therefore, we created MicroRNA Amplification and Recognition through Locked-nucleic-acid in situ hybridizatioN (MARLIN), which was developed and optimized utilizing multiplex immunofluorescence staining, and locked nucleic acid (LNA) probes targeted to a miRNA. This method can quantify miRNA with multiplexed protein expression, which allows the quantification of intracellular and extracellular miRNA within the tumor microenvironment (TME) with high sensitivity and reproducibility. The combined use of miRNA detection and protein capture assays can also provide a comprehensive understanding of cellular functions and regulatory mechanisms within that TME.
- 7 October 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 224,p. e68617
MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method
When using traditional probe-based in situ hybridization (ISH) imaging detection methods, microRNAs (miRNAs) are difficult to capture due to their size, which ranges from 19 to 25 nucleotides. However, as miRNAs are key epigenetic regulators that contribute to normal physiology and numerous pathological conditions, understanding the spatiotemporal behavior of miRNAs is important to unravel their function at the cellular and subcellular levels. This creates a clear need for adequate detection and visualization techniques. Therefore, we created MicroRNA Amplification and Recognition through Locked-nucleic-acid in situ hybridizatioN (MARLIN), which was developed and optimized utilizing multiplex immunofluorescence staining, and locked nucleic acid (LNA) probes targeted to a miRNA. This method can quantify miRNA with multiplexed protein expression, which allows the quantification of intracellular and extracellular miRNA within the tumor microenvironment (TME) with high sensitivity and reproducibility. The combined use of miRNA detection and protein capture assays can also provide a comprehensive understanding of cellular functions and regulatory mechanisms within that TME.
- 7 October 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 224,p. e68617
MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method
When using traditional probe-based in situ hybridization (ISH) imaging detection methods, microRNAs (miRNAs) are difficult to capture due to their size, which ranges from 19 to 25 nucleotides. However, as miRNAs are key epigenetic regulators that contribute to normal physiology and numerous pathological conditions, understanding the spatiotemporal behavior of miRNAs is important to unravel their function at the cellular and subcellular levels. This creates a clear need for adequate detection and visualization techniques. Therefore, we created MicroRNA Amplification and Recognition through Locked-nucleic-acid in situ hybridizatioN (MARLIN), which was developed and optimized utilizing multiplex immunofluorescence staining, and locked nucleic acid (LNA) probes targeted to a miRNA. This method can quantify miRNA with multiplexed protein expression, which allows the quantification of intracellular and extracellular miRNA within the tumor microenvironment (TME) with high sensitivity and reproducibility. The combined use of miRNA detection and protein capture assays can also provide a comprehensive understanding of cellular functions and regulatory mechanisms within that TME.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer
SLC38A2 and SLC7A8 are direct target genes of the SWI/SNF complex.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer
SLC38A2 and SLC7A8 are direct target genes of the SWI/SNF complex.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer
Inactivation of the SWI/SNF complex sensitizes cells to SLC38A2 inhibition and SLC7A8 overexpression.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer
Inactivation of the SWI/SNF complex sensitizes cells to SLC38A2 inhibition and SLC7A8 overexpression.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer
The effects of SLC38A2 inhibition alone or in combination with anti-PD-L1 on tumor microenvironment.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer
The effects of SLC38A2 inhibition alone or in combination with anti-PD-L1 on tumor microenvironment.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer
SLC38A2 regulates CAR T cell-based assault.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer
SLC38A2 regulates CAR T cell-based assault.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer
SLC38A2 inhibition reduces the marker of cell proliferation in ARID1A-inactivated OCCCs.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer
SLC38A2 inhibition reduces the marker of cell proliferation in ARID1A-inactivated OCCCs.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer
ARID1A regulates alanine metabolism in OCCC cells.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer
ARID1A regulates alanine metabolism in OCCC cells.